About Enterix
Enterix is a Healthcare company based in Edison (United States) founded in 1997 by Robert Max Mawhinney and Howard Chandler, and was acquired by Clinical Genomics in September 2013. Cancer screening tests for colorectal detection are developed. Enterix has raised $7.5 million across 1 funding round from investors including Macquarie Group, Quest Diagnostics and DeutscheAM. Its chief executive, as recorded, is Craig Sands. Enterix offers products and services including InSure One Test Kit and Fecal Immunochemical Test. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Gastrointestinal Cancer. Its legal entity is ENTERIX, INC. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Enterix developed screening tests for cancer. Its lead product was InSure FIT, which is a fecal immunochemical test for the early detection of colorectal cancer. The test is FDA-approved and CLIA-waived. In Sept 2006, Quest Diagnostics acquired Enterix for approximately 43M in cash. In Oct 2013, Quest sold the business unit to Clinical Genomics.
- Headquarters Edison, United States
- Founders Robert Max Mawhinney, Howard Chandler
- Stage Acquired
- SectorsHealthcare
- Website insuretest.com
- Social LinkedIn Facebook Instagram YouTube
- Acquired by Clinical Genomics (Sep 2013)
- Legal Name Enterix, Inc
- Total Equity Funding$7.5M (USD)
in 1 rounds
- Latest Funding Round$7.5M (USD), Series A
Jul 2001
- InvestorsMacquarie Group
& 4 more
- Acquired by
Products & Services of Enterix
Enterix offers a comprehensive portfolio of products and services, including InSure One Test Kit and Fecal Immunochemical Test.
At-home test for detecting blood in stool to screen for colorectal cancer.
Simple brush-based method for sample collection and mailing.
Apps and channels of Enterix
its YouTube channel InSure ONE Test has 307 subscribers and 18 videos.
Videos from Enterix
The most watched videos on Enterix's YouTube channel, InSure ONE Test (307 subscribers). Click a video to play it here.
More on InSure ONE Test.
Funding Insights of Enterix
Enterix has successfully raised a total of $7.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.5 million completed in July 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.5M
- Total Rounds 1
- Last Round Series A — $7.5M
- First Round $7.5M
(Jul 2001)
- Investors Count 3
All 1 funding rounds of Enterix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2001 | $7.5M | Series A | – | DeutscheAM |
5 investors in total: 5 institutional.
Investors in Enterix
Enterix has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Macquarie Group, Quest Diagnostics and DeutscheAM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| innovationcapital.net | ||||
Manages diversified investment portfolios across various asset classes. | 2015 | deutscheam.com | Frankfurt, Germany | |
A global financial services organization with Australian heritage is operated. | 1969 | macquarie.com | Sydney, Australia | |
Integrated diagnostic and IT services are provided to healthcare organizations. | 1967 | questdiagnostics.com | Madison, United States | |
| clinicalgenomics.com |
Investor details for Enterix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enterix
3 people are tracked at Enterix (3 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Max Mawhinney | Co-Founder | Leadership |
Howard Chandler | Co-Founder | Leadership |
Craig Sands | CEO & President | Leadership |
Complete people profiles for Enterix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enterix
4 dated milestones of Enterix across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Enterix is founded.
- Funding First funding round of $7.5M.
- Exit Acquired by Quest Diagnostics.
- Exit Acquired by Clinical Genomics.
Competitors of Enterix
Enterix has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Enterix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enterix
The website of Enterix (insuretest.com) receives about 8.3K visits a month.
- Monthly visits8.3K
▲ 11.2% vs previous month
Websites whose visitors overlap most with Enterix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cms.hhs.gov | cms.hhs.gov | 100% | – | ||
| polymedco.com | 93% | #8,808,668 | View details | ||
| exactlabs.com | 92% | 8K | #2,940,507 | View details | |
ezdetect.com | ezdetect.com | 74% | – | ||
| lacolon.com | 57% | 25.9K | #1,212,820 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Enterix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Enterix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enterix
Complete news archive for Enterix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enterix
Enterix was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Enterix is headquartered in Edison, United States. It is registered at Edison, New Jersey, United States.
Craig Sands is the CEO of Enterix, as recorded in our data.
Enterix is a funded company, having raised a total of $7.5M across 1 funding round to date. The company's 1st funding round was a Series A of $7.5M, raised on Jul 2001.
Enterix developed screening tests for cancer. Its lead product was InSure FIT, which is a fecal immunochemical test for the early detection of colorectal cancer. The test is FDA-approved and CLIA-waived. In Sept 2006, Quest Diagnostics acquired Enterix for approximately 43M in cash. In Oct 2013, Quest sold the business unit to Clinical Genomics.
Enterix's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.
Enterix offers InSure One Test Kit and Fecal Immunochemical Test.
Enterix has 5 investors. Key investors include Macquarie Group, Quest Diagnostics, DeutscheAM, Innovation Capital, and Clinical Genomics.
Enterix operates through Enterix, Inc.
Yes. Enterix was acquired by Clinical Genomics in September 2013.